Structured evidence table for Glutamine Gut Health Randomized Trial, generated from 1 reusable source document in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Glutamine Gut Health Randomized Trial | 1 2 3 4 5 5 6 7 6 7 Irritable bowel syndrome (IBS) is a chronic disorder of gut–brain interaction characterized by recurrent abdominal pain associated with altered bowel habits, in the absence of identifiable structural abnormalities []. | 3 | Šuran Jelena (2026) | IBS and SIBO: Gut Microbiota, Pathophysiology, and Non-Pharmacological Interventions |
| Glutamine Gut Health Randomized Trial | Early studies reported SIBO in up to 60–78% of IBS cases based on lactulose breath testing [,,], though later investigations using more rigorous methods found lower prevalences (e.g., 4–20%) [,]. | 3 | Šuran Jelena (2026) | IBS and SIBO: Gut Microbiota, Pathophysiology, and Non-Pharmacological Interventions |
| Glutamine Gut Health Randomized Trial | Moreover, increasing evidence implicating the gut microbiota in IBS/SIBO has spurred interest in interventions that modulate microbial communities. | 3 | Šuran Jelena (2026) | IBS and SIBO: Gut Microbiota, Pathophysiology, and Non-Pharmacological Interventions |
| Glutamine Gut Health Randomized Trial | It affects an estimated 5–10% of the global population and is more common in women, imposing a significant burden on quality of life and healthcare resources []. | 3 | Šuran Jelena (2026) | IBS and SIBO: Gut Microbiota, Pathophysiology, and Non-Pharmacological Interventions |
Source documents